Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaliproden in mild-to-moderate Alzheimer's disease
NCT00285025Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2005
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of xaliproden in Alzheimer's disease (AD), sponsored by Sanofi. Started Mar 2005; status: completed.
02
Drugs
xaliproden
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00285025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285025.